Phaseline

Companies › BriaCell Therapeutics

BriaCell Therapeutics: clinical trials, targets and expected readouts

3 active drug programs in 29 registered trials: 15 Phase 2, 10 Phase 1, 4 Phase 3; Oncology; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Interferon Alfa-2B
Interferon alpha/beta receptor agonist
IFNAR1, IFNAR2Phase 3Breast Cancer; Colorectal Neuroendocrine Tumor G1; Prostate Adenocarcinoma; Polycythemia VeraDec 2027
Retifanlimab
Programmed cell death protein 1 antagonist
PDCD1Phase 3Breast Cancer; Anatomic Stage IV Breast Cancer AJCC v8; Merkel Cell Carcinoma; Recurrent Glioblastoma …Dec 2027
SV-BR-1-GM
Allogeneic whole cell breast tumor cell line transfected with CSF2 gene encoding GM-CSF; p
CSF2Phase 3Breast CancerDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04445844RetifanlimabPhase 2Anatomic Stage IV Breast Cancer AJCC v8OncologyJun 2025
NCT05594290RetifanlimabPhase 2Merkel Cell CarcinomaOncologyNov 2026
NCT06160206RetifanlimabPhase 2Recurrent GlioblastomaOncologyNov 2026
NCT04494009RetifanlimabPhase 2Esophageal CancerOncologyDec 2026
NCT05455697RetifanlimabPhase 1Diffuse Large B-Cell LymphomaOncologyJan 2027
NCT06056895RetifanlimabPhase 2Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8OncologyJan 2027
NCT00569127Interferon Alfa-2BPhase 3Colorectal Neuroendocrine Tumor G1OncologyJan 2027
NCT06320405RetifanlimabPhase 1Advanced Malignant Solid NeoplasmOncologyApr 2027
NCT03899987Interferon Alfa-2BPhase 2Prostate AdenocarcinomaOncologyApr 2027
NCT05345002RetifanlimabPhase 2GliomaOncologyJun 2027
NCT04438824RetifanlimabPhase 2Well-differentiated/Dedifferentiated LiposarcomaOncologyJun 2027
NCT04577014RetifanlimabPhase 1Soft Tissue SarcomaOncologySep 2027
NCT06149481RetifanlimabPhase 1Metastatic Colorectal CancerOncologyOct 2027
NCT06072612SV-BR-1-GMPhase 3Breast CancerOncologyDec 2027
NCT06072612RetifanlimabPhase 3Breast CancerOncologyDec 2027
NCT07219576RetifanlimabPhase 1Non Small Cell Lung CarcinomaOncologyDec 2027
NCT06072612Interferon Alfa-2BPhase 3Breast CancerOncologyDec 2027
NCT06389799RetifanlimabPhase 2Dedifferentiated LiposarcomaOncologyDec 2027
NCT04470024RetifanlimabPhase 1Cancer of the Head and NeckOncologyDec 2027
NCT05083754RetifanlimabPhase 1Glioblastoma MultiformeOncologyJan 2028
NCT06896188RetifanlimabPhase 1Pancreatic AdenocarcinomaOncologyMar 2028
NCT05870475Interferon Alfa-2BPhase 2Polycythemia VeraOncologyMar 2028
NCT04968106RetifanlimabPhase 2Resectable SarcomaOncologyApr 2028
NCT07425054RetifanlimabPhase 2Anal CancerOncologyJan 2029
NCT05743595RetifanlimabPhase 1Unmethylated GlioblastomaOncologyMar 2029
NCT04225039RetifanlimabPhase 2GlioblastomaOncologyApr 2029
NCT05177133RetifanlimabPhase 2Gastric AdenocarcinomaOncologyNov 2029
NCT04374305RetifanlimabPhase 2Neurofibromatosis Type 2OncologyDec 2029
NCT07468136RetifanlimabPhase 1Anaplastic OligodendrogliomaOncologyOct 2030

From the company's SEC filings

Cash and short-term investments of $21m on 2026-07-31; operating cash outflow about $29m a year; runway about 9 months at that burn, to Apr 2027; 5 of 6 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Targets

CSF2 (1) PDCD1 (1) IFNAR1 (1) IFNAR2 (1)

Companies with the same targets

Akeso AstraZeneca Sichuan Baili Pharmaceutical Innovent Biologics (Suzhou) Shanghai Henlius Biotech Shenyang Sunshine Pharmaceutical Regeneron Pharmaceuticals Ono Pharmaceutical Mabwell (Shanghai) Bioscience Johnson & Johnson (Janssen)

Companies built like this

Genelux Imunon Actuate Therapeutics Actinium Pharmaceuticals pharmaand

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.